PERIPHERAL T/NK CELL LYMPHOMAS

Poster number

Title

Submitting author

City and Country

209

A phase 2b open-label single arm study to evaluate the efficacy and safety of HBI-8000 (tucidinostat) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)

Won Seog Kim

Seoul, Korea

210

A Phase 2b study to evaluate the efficacy and safety of Tucidinostat (HBI-8000) in Japanese patients with relapsed or refractory adult T-cell leukemia-lymphoma (ATL)

Koji Izutsu

Tokyo, Japan

211

A phase II trial of reduced dose brentuximab vedotin for cutaneous T-cell lymphomas.

Niloufer Khan

New York, NY, USA

212

Population-based cohort study of the efficacy of Brentuximab-Vedotin in relapsed systemic Anaplastic Large Cell Lymphoma using Public Health England data

Sarah Halligan

Nottingham, UK

213

Phase 1 Results of anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T cell Lymphoma and Correlation with Gene Expression Profile

Christiane Querfeld

Duarte, CA, USA

214

Romidepsin and carfilzomib in relapsed / refractory peripheral T-cell lymphoma with assessment of H23B as a predictive biomarker – the UK NCRI seamless Phase 1/2 RomiCar trial

Graham Collins

Oxford, UK

215

Sintilimab plus Chidamide for Relapsed/Refractory (r/r) Extranodal NK/T Cell Lymphoma (ENKTL): A Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Huiqiang Huang

Guangzhou, China

216

A Phase Ib study of an oral PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T cell lymphoma

Lugui Qiu

Tianjin, China

217

Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

Freek Meeuwes

Groningen, Netherlands

218

ROMIDEPSIN-CHOEP PLUS UP-FRONT STEM-CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA (PTCL): FIRST ANALYSIS OF THE PHASE II FIL-PTCL13 STUDY

Annalisa Chiappella

Milano, Italy

219

Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients With Peripheral T-cell Lymphoma With Less Than 10% CD30 Expression (SGN35‑032, Trial in Progress)

Deepa Jagadeesh

Cleveland, OH, USA

220

Peripheral T-cell lymphomas involving central nervous system: a report from the Czech Lymphoma Study Group Registry

Heidi Mocikova

Prague, Czech Republic

221

Clinical characteristics and outcomes of adult lymphoma-associated hemophagocytic lymphohistiocytosis (HLH)

Christina Lee

New York, NY, USA

222

Hepatosplenic T cell lymphoma: Clinical Characteristics and Survival

Firas Baidoun

Cleveland, OH, USA

223

Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0.

Massimo Federico

Modena, Italy

224

Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas

Wei Wang

Beijing, China

225

Impact of DUSP22 rearrangement on the prognosis of systemic ALK-negative anaplastic large cell lymphoma: a LYSA and TENOMIC study

David Sibon

Paris, France

226

Subcutaneous panniculitis-like T-cell lymphoma: molecular and mutational characterization compared with lupus panniculitis and histopathologic overlapping cases

Salma Machan

Madrid, Spain

227

Characterization of the oncogenic phenotype in extranodal natural killer/T-cell lymphoma, nasal type through gene expression profile. Spanish Lymphoma Group GELTAMO.

Eva González-Barca

Barcelona, Spain

228

Peripheral T-cell lymphoma: molecular profiling distinguishes subclasses, recognizes the tumor architecture and identifies prognostic markers.

Marta Rodríguez

Madrid, Spain

229

Mutational analysis of the different Nodal Peripheral T-cell lymphoma subclasses

Laura Tomas-Roca

Madrid, Spain